Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Cert. of designation
Appointed director
Bionik Laboratories Corp. (BNKL) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/16/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "SUBSCRIPTION AGREEMENT",
"BIONIK LABORATORIES CORP. CONVERTIBLE PROMISSORY NOTE",
"Signature on the Following Page 5 In Witness Whereof, the Company has caused this Note to be signed by its duly authorized officer on the date hereinabove written. Bionik Laboratories Corp. By: Name: Title: HOLDER: Name: SIGNATURE PAGE TO PROMISSORY NOTE"
06/16/2023 8-K Unregistered Sales of Equity Securities, Financial Statements and Exhibits  Interactive Data
05/23/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Bionik Laboratories Reports a Significant Increase in Patient Volume at its Acquired Rehabilitation Center in Florida"
05/04/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Bionik Laboratories Enters into Distribution Agreement with Pro-Med Technology for the Sale of InMotion® Robotic Devices in Hong Kong"
04/26/2023 8-K Quarterly results
02/23/2023 8-K Entered into an underwriting agreement for the issuance and sale of notes
Docs: "SUBSCRIPTION AGREEMENT",
"BIONIK LABORATORIES CORP. CONVERTIBLE PROMISSORY NOTE"
02/08/2023 8-K Quarterly results
01/20/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
12/20/2022 8-K Quarterly results
11/17/2022 8-K Quarterly results
11/09/2022 8-K Quarterly results
11/07/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Bionik Laboratories to Present at the Q4 Virtual Investor Summit"
10/13/2022 8-K Amended existing or entered into new employment agreement with an officer
Docs: "SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment to the Employment Agreement dated as of the Start Date , as amended pursuant to that First Amendment to Employment Agreement dated October 15, 2021 , by and between Bionik Laboratories Corp., a Delaware corporation, and Richard Russo, is made as of the 6th day of October, 2022 , by and between the Company and the Employee . RECITALS WHEREAS, the Company and the Employee are parties to the Agreement; and WHEREAS, the Company and the Employee desire to amend the Agreement as more particularly set forth herein; and WHEREAS, Section 6.6 of the Agreement provides, in part, that no amendment to the Agreement shall be valid or binding unless set forth in writing and duly executed by both of the parties thereto. NOW, THEREFORE, in cons...",
"EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT, is made as of the Start Date , by and between BIONIK LABORATORIES CORP., a Delaware corporation , and Dan Gonsalves . RECITALS WHEREAS, the Company, directly or through its subsidiaries, is engaged in the business of medical device research, development and production; and WHEREAS, the Company and the Employee have agreed to enter into an employment relationship upon the terms and subject to the conditions hereinafter set forth. NOW THEREFORE, in consideration of the mutual covenants and promises herein contained and other good and valuable consideration, the parties agree as follows: ARTICLE 1- EMPLOYMENT AND DUTIES 1.1 Appointment . Subject to the terms and conditions of this Agreement, the Company hereby agrees to employ the employee, and ...",
"Bionik Laboratories Appoints Richard Russo, Jr. as Chief Executive Officer and Dan Gonsalves as Chief Financial Officer"
09/08/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Bionik Laboratories Acquires Florida Rehabilitation Center; First in Strategic National Rollout"
09/07/2022 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financia...
Docs: "BALANCE DUE AT CLOSING",
"BIONIK LABORATORIES CORP. SECURED CONVERTIBLE PROMISSORY NOTE",
"COLLATERAL PLEDGE AGREEMENT"
09/01/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "BIONIK Laboratories to Present at National Investment Banking Association Conference"
08/31/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/16/2022 8-K Quarterly results
08/10/2022 8-K Quarterly results
08/09/2022 8-K Quarterly results
07/21/2022 8-K Quarterly results
07/06/2022 8-K Quarterly results
06/14/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
04/06/2022 8-K Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits  Interactive Data
02/09/2022 8-K Quarterly results
12/20/2021 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
11/10/2021 8-K Quarterly results
Docs: "Condensed Consolidated Balance Sheets September 30, 2021 March 31, 2021 Assets Current assets: Cash and cash equivalents $ 4,774,663 $ 608,348 Accounts receivable 71,470 451,905 Prepaid expenses and other current assets 1,549,265 1,680,557 Inventories 788,871 692,163 Total current assets 7,184,269 3,432,973 Equipment, net 57,570 93,577 Intangible assets, net 937,271 976,551 Goodwill 4,282,984 4,282,984 Total assets $ 12,462,094 $ 8,786,085 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 377,908 $ 454,809 Accrued liabilities 779,901 760,026 PPP loan - 459,912 Convertible notes 8,491,627 - Demand loans, current portion - 2,152,334 Current portion of deferred revenue 195,063 268,083 Total current liabilities 9,844,499 4,095,164 Demand loans, net of current portio..."
10/15/2021 8-K Amended existing or entered into new employment agreement with an officer
Docs: "FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment to the Employment Agreement dated as of the Start Date by and between Bionik Laboratories Corp., a Delaware corporation, and Richard Russo, is made as of the 15 th day of October, 2021, by and between the Company and the Employee . RECITALS WHEREAS, the Company and the Employee are parties to the Agreement; and WHEREAS, the Company and the Employee desire to amend the Agreement as more particularly set forth herein; and WHEREAS, Section 6.6 of the Agreement provides, in part, that no amendment to the Agreement shall be valid or binding unless set forth in writing and duly executed by both of the parties thereto. NOW, THEREFORE, in consideration of the mutual promises and covenants contained in this Agreement, the parties hereto a..."
09/22/2021 8-K Quarterly results
08/12/2021 8-K Quarterly results
Docs: "BIONIK Laboratories Reports Fiscal 2022 Q1 Financial Results Revenues Increase 160% Over Same Period in Prior Year $5M Capital Raise to Convert at $9.50/Share Showing Confidence in Bionik"
07/29/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "BIONIK Laboratories Announces $5 Million Capital Raise through Issuance of Convertible Notes"
07/21/2021 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...
Docs: "Form of Subscription Agreement",
"Form of Convertible Promissory Note"
07/19/2021 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "BIOIK Laboratories Announces Resignation of CEO, Names Interim CEO"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy